Salit RB, Hexner EO, Gagelmann N, Kröger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus , Leukemia: 2025
Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer , Cell Rep Med, 6(9): 2025,102301.
Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM. Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial , Nat Med, 31(9): 2025,3205
Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz M, Asada N, Ayuk FA, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler EPDm, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T. Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC , Blood Adv. , 9(18): 2025,4640-4653.
Akahoshi Y, Portelli J, Katsivelos N, Louloudis IE, Aguayo-Hiraldo PI, Ayuk FA, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Hexner EO, Kitko CL, Kraus S, Merli P, Olson TS, Pasic I, Qayed M, Reshef R, Schechter-Finkelstein T, Marx J, Ullrich E, Vasova I, Weber D, Wölfl M, Zeiser R, Baez J, Eng GW, Gleich S, Kowalyk SM, Morales G, Spyrou N, Young R, DeFilipp Z, Hogan WJ, Nakamura R, Levine JE, Ferrara JLM The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD , Blood Adv., 15: 2025
Svoboda J, Hexner E, June CH Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply. , N Engl J Med, 393(6): 2025,620.
Verschraegen CF, Hashibe M, Neill US, Pirl W, Hexner EO, O'Connell A; NASDC Consortium. NCI Awardee Skills Development Consortium (NASDC): a Successful Novel Educational Effort to Maintain Early Academic Competitiveness: PART 1-Overview of the NASDC Coordinating Center , J Cancer Educ, 10: 2025
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. , N Engl J , 392(18): 2025,1824-1835.
Hexner EO, DeFilipp Z. Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation Strategies , Am J Hematol, 100: 2025,Suppl 3:30-39.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med, 31(4): 2025,1134-1144
